Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant

The adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends thos...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Vaccine Immunol
Hoofdauteurs: Chen, Wilbur H., Jackson, Lisa A., Edwards, Kathryn M., Keitel, Wendy A., Hill, Heather, Noah, Diana L., Creech, C. Buddy, Patel, Shital M., Mangal, Brian, Kotloff, Karen L.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society for Microbiology 2016
Onderwerpen:
Vaccines
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4711091/
https://ncbi.nlm.nih.gov/pubmed/26561390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00475-15
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items